Want to see REGN full AI Analyst Report?
REGN Stock Chart & Stats
$833.56
$20.13(3.07%)
At close: 4:00 PM EDT
$833.56
$20.13(3.07%)
Day’s Range― - ―
52-Week Range$541.00 - $859.34
Previous CloseN/A
Volume174.31K
Average Volume (3M)683.91K
Market Cap
$77.27B
Enterprise Value$60.80K
Total Cash (Recent Filing)$7.99B
Total Debt (Recent Filing)$1.99B
Price to Earnings (P/E)18.1
Beta0.58
Next Earnings
Oct 30, 2026EPS Estimate
15.99Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)41.88
Shares Outstanding101,137,840
10 Day Avg. Volume847,052
30 Day Avg. Volume683,909
Financial Highlights & Ratios
PEG Ratio3.38
Price to Book (P/B)2.58
Price to Sales (P/S)5.63
P/FCF Ratio19.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$849.18Price Target Upside1.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)54.51
Revenue Forecast (FY)$17.06B
Bulls Say, Bears Say
Bulls Say
Dupixent Growth And Collaboration StrengthDupixent is showing substantial scale, patient growth, and multi-indication penetration, supporting a durable commercial engine. Its collaboration with Sanofi also broadens global reach and increases profit contribution, helping offset pressure in other products while funding continued innovation.
Diversified Pipeline And New Approved TherapyPasatru approval adds a new marketed therapy in a rare disease with limited treatment options, while the broad clinical portfolio creates multiple avenues for future growth. This diversification can reduce reliance on individual products and extend the company’s long-term innovation runway.
Strong Balance Sheet And Cash GenerationLow leverage and robust cash conversion give Regeneron meaningful financial flexibility to sustain high R&D investment, support launches, pursue business opportunities, and return capital. A strong balance sheet also improves resilience when product transitions or development programs create temporary earnings variability.
Bears Say
Legacy EYLEA Erosion And CompetitionThe sharp decline in legacy EYLEA creates a material transition burden because the franchise remains an important commercial contributor. Biosimilar launches and ongoing conversion to EYLEA HD can pressure revenue, mix, and execution before the replacement product fully offsets the erosion.
Manufacturing Disruption Reduced MarginsThe Limerick disruption demonstrates that operational interruptions can affect reported profitability even when underlying product margins remain strong. Although production resumed, recovery and normalization still require execution, and any recurrence could create additional cost absorption pressure or constrain product availability.
Oncology Development And Adoption ChallengesOncology offers meaningful opportunity but carries elevated development and commercialization uncertainty for Regeneron. Missed endpoints, difficult solid-tumor biology, and limited late-line markets can delay returns on substantial R&D spending and make pipeline diversification less dependable in the near term.
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $541.00 and its highest was $859.34 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $77.27B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Oct 30, 2026 which is in 29 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Jul 30, 2026. The company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.157 by $4.133.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.94 which represents an annual dividend yield of 0.49%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 15.99.
How many shares outstanding does Regeneron have?
Regeneron has 101,137,840 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $14.29 in its last earnings report, beating expectations of $10.157. Following the earnings report the stock price went up 6.172%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$849.18 (1.87% Upside)
$849.18 (1.87% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 84%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 471.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.55%
12-Months-Change
Fundamentals
Return on Equity
0.49%
Trailing 12-Months
Asset Growth
9.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
REGN Company Deck
REGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and financial momentum driven by Dupixent, rapid EYLEA HD adoption, robust Libtayo growth, an expansive and advancing pipeline with several near-term regulatory catalysts (cemdisiran, PNH data, garetosmab), and a healthy balance sheet with active capital returns. Offsetting risks include a sizable YoY decline for legacy EYLEA U.S., a temporary manufacturing disruption that pressured GAAP margins, timing uncertainty around the EYLEA HD prefilled syringe approval, and acknowledged challenges in oncology development. On balance, positive operating performance, clear growth drivers, and a deep pipeline outweigh the execution and timing risks described.View all REGN earnings summariesREGN Revenue Breakdown
43.99% Net product sales
51.11% Collaboration revenue
4.90% Other revenue
REGN Stock 12 Month Forecast
Average Price Target
$849.18
▲(1.87% Upside)
Technical Analysis
Ownership Overview
2.02% Insiders
26.49% Mutual Funds
18.67% Other Institutional Investors
20.83% Public Companies and Individual Investors